SCHEMBL19967792

SCHEMBL19967792

O=C(N[C@@H](CO)c1nc(-c2nc3ccccc3[nH]2)no1)c1ccc(F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.48
HTT P42858 2/20 0.48
ALDH1A1 P00352 2/20 0.48
GAA P10253 1/20 0.48
NPC1 O15118 3/20 0.48
RAB9A P51151 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
TP53 P04637 1/20 0.48
PKM P14618 1/20 0.48
HSD17B10 Q99714 1/20 0.48
POLB P06746 2/20 0.45
HPSE Q9Y251 1/20 0.43
PAK4 O96013 1/20 0.42
CDK2 P24941 1/20 0.42
FPR1 P21462 2/20 0.42
STK33 Q9BYT3 1/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
APLNR P35414 2/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19835720 0.82 LMNA (0.44) KDM4EHTTALDH1A1GAANPC1
SCHEMBL18105164 0.82 LMNA (0.44) KDM4EHTTALDH1A1GAANPC1
SCHEMBL18105158 0.80 MAPK1 (0.46) HTTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL19835963 0.80 MAPK1 (0.46) HTTNPC1RAB9ASMN1; SMN2TP53
SCHEMBL18104942 0.80 LMNA (0.43) KDM4EHTTNPC1RAB9APAK4
SCHEMBL19836122 0.80 LMNA (0.43) KDM4EHTTNPC1RAB9APAK4
SCHEMBL29582930 0.80 LMNA (0.43) KDM4EHTTNPC1RAB9APAK4
SCHEMBL19949365 0.80 LMNA (0.46) ALDH1A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL18104971 0.80 LMNA (0.46) ALDH1A1NPC1RAB9ASMN1; SMN2TP53
SCHEMBL18104897 0.80 HDAC4 (0.53) PAK4CDK2LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072708-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY (JP) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072708-A1 NOVEL OXADIAZOLE DERIVATIVE AND PHARMACEUTICAL CONTAINING SAME APP, BACE1, PSEN1 KDM4E 2555/4885HTT 18/4885ALDH1A1 3540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.